Pre-market hot trades in US stocks: Annovis Bio pre-market down 7.26%; Urban One pre-market down 6.59%

Pre-market Hot Trades in US Stocks

Annovis Bio is down 7.26% in pre-market trading. Based on recent news,

1. On November 17, Annovis Bio released new biomarker data showing that amyloid co-morbidity is associated with accelerated cognitive decline in Parkinson's disease patients. This news raised market concerns, leading to a drop in stock price.

2. On November 17, Annovis Bio reported that its drug buntanetap improved cognitive function in Parkinson's disease patients, especially in those with amyloid co-morbidity. However, the market remains skeptical about the long-term efficacy of the drug, further exacerbating stock price volatility.

3. On November 18, despite positive results from the Phase III clinical trial of Annovis Bio's buntanetap, investors are cautious about its future market performance, leading to a pre-market decline in stock price. The biotechnology sector has been volatile recently, and investors should exercise caution.

Urban One is down 6.59% in pre-market trading. Based on recent key news:

1. On November 14, Urban One announced the exchange of its existing 7.375% senior secured notes for newly issued 7.625% notes, raising concerns in the market about the company's debt structure, resulting in a drop in stock price.

2. On November 14, technical sentiment signals indicated a sell, and the market holds a pessimistic view of the company's future performance, further pushing the stock price down.

3. On November 14, the company's market capitalization was $29.62 million, with a trading volume of 17,773, indicating a decrease in market interest in the stock. The media industry has shown weak performance recently, with significant capital outflows.

Top Gainers in Pre-market US Stocks

Click Holdings/BVI is up 34.42% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Lobo Tech is up 33.57% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Aspire Biopharma is up 27.93% in pre-market trading. Based on recent key news:

1. On November 14, Aspire Biopharma submitted an amendment to its quarterly report for the period ending September 30, 2025. This move may draw market attention to the company's financial condition, leading to a significant pre-market increase in stock price. Source: EDGAR system. The biopharmaceutical industry has been volatile recently